CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
43.92
-0.06 (-0.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close43.98
Open43.94
Bid36.02 x 800
Ask0.00 x 800
Day's Range43.65 - 44.80
52 Week Range22.22 - 66.26
Volume290,243
Avg. Volume543,340
Market Cap2.373B
Beta (3Y Monthly)2.94
PE Ratio (TTM)N/A
EPS (TTM)-3.74
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.05
Trade prices are not sourced from all markets
  • What Kind Of Shareholders Own CRISPR Therapeutics AG (NASDAQ:CRSP)?
    Simply Wall St.4 days ago

    What Kind Of Shareholders Own CRISPR Therapeutics AG (NASDAQ:CRSP)?

    The big shareholder groups in CRISPR Therapeutics AG (NASDAQ:CRSP) have power over the company. Generally speaking, as...

  • How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?
    Simply Wall St.4 days ago

    How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?

    A look at the shareholders of CRISPR Therapeutics AG (NASDAQ:CRSP) can tell us which group is most powerful...

  • Zacks9 days ago

    Fed Week Begins in the Green

    Fed Week Begins in the Green

  • Moody's14 days ago

    J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns definitive ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB

    Rating Action: Moody's assigns definitive ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019- OSB. Global Credit Research- 13 Jun 2019.

  • Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
    American City Business Journals14 days ago

    Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray

    The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks15 days ago

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Is the Newest Gene Editing Stock a Buy?
    Motley Fool16 days ago

    Is the Newest Gene Editing Stock a Buy?

    Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.

  • CRISPR Therapeutics Up on Collaboration Expansion by Vertex
    Zacks17 days ago

    CRISPR Therapeutics Up on Collaboration Expansion by Vertex

    CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

  • Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?
    Motley Fool18 days ago

    Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

    Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.

  • Benzinga20 days ago

    Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion

    Gene editing is an emerging field, and  Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )  is plunging headlong into it with two deals announced Thursday after the market close.  Expanded Collaboration, Licensing ...

  • Barrons.com20 days ago

    Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition

    Analysts are cheering a new acquisition by Vertex Pharmaceuticals to jump start its gene-therapy program.

  • Vertex Expands Collaboration With CRISPR, Acquires Exonics
    Zacks20 days ago

    Vertex Expands Collaboration With CRISPR, Acquires Exonics

    Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.

  • Benzinga20 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Vertex enters Duchenne field with $245M buy of Exonics
    American City Business Journals21 days ago

    Vertex enters Duchenne field with $245M buy of Exonics

    Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.

  • Business Wire21 days ago

    Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.

  • Vertex Selects Triple Combo Regimen for Regulatory Submission
    Zacks27 days ago

    Vertex Selects Triple Combo Regimen for Regulatory Submission

    Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

  • 3 Top Gene Therapy Stocks That Could Soar
    InvestorPlace28 days ago

    3 Top Gene Therapy Stocks That Could Soar

    Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually "turning off" the genes causing problems, gene therapy has the potential to change the game when it comes to biotech stocks and healthcare.That's great news, as there are more than 10,000 different disorders and diseases caused by faulty genes.With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize in these cutting-edge treatments could see their drugs hit the market that much faster. And yet, the recent market sell-off has caused many of the biotech stocks looking at gene therapy to crater. Given their game-changing potential, these days many stocks in the sector could be considered bargains.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome more than others. * 7 Stocks to Sell Amid an Escalating Trade War Which gene-therapy biotech stocks have great potential to soar over the long haul? Here are three stocks to buy that could do just that. Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP)Source: Shutterstock Clustered Regularly Interspaced Short Palindromic Repeats is a mouthful to say, which is why scientists have shortened it to just CRISPR. CRISPR is the latest method of gene editing and offers cheaper, simpler and faster slicing and dicing of genes. As its name implies, CRISPR Therapeutics (NASDAQ:CRSP) uses the technique.CRSP stock is targeting blood diseases such as beta-thalassemia and sickle cell disease- which are caused by the same mutation. The beauty of this is that the biotech has been able to move ahead at the same time for both indications. Partnering with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX), CRSP's lead candidate -- CTX001 -- started phase 1 clinical trials this past February. This trial marks the first time in history that a human trial for a CRISPR-based product has been conducted.Naturally, a lot is riding on the trial- especially with the drug winning FDA fast track status. If results are even somewhat positive, CRSP stock could surge higher.But CTX001 isn't the only drug in CRSP's arsenal. The firm is working one several oncology products as well as new gene editing therapies for muscular dystrophy and cystic fibrosis. These drugs could provide plenty of upside as well down the road.In the end, if you're looking for biotech stocks to buy that are looking at gene therapy, CRISPR Therapeutics could be a major star. uniQure NV (QURE)Source: Shutterstock When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That's because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.This includes the biotech stock's latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication -- AMT-061 -- into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.Elsewhere, the firm has started trials for the first gene therapy targeting Huntington's disease and has gene therapies for congestive heart failure in pipelines. All of these are much more "popular" issues and should help QURE actually see prescription growth if successful. * 7 Stocks to Buy for June Like most clinical-stage biotech stocks, QURE is a gamble. But it's a more calculated risk than most given its history and how great its previous results were. Voyager Therapeutics (VYGR)Source: Shutterstock When it comes to clinical stage biotech stocks, it pays to look at partnerships. For gene therapy play Voyager Therapeutics (NASDAQ:VYGR), partnerships include biotech giant AbbVie (NYSE:ABBV), neurological specialist Neurocrine Biosciences (NASDAQ:NBIX) and major pharma stock Sanofi (NASDAQ:SNY). All three of those major players have provided VYGR with some major cash infusions to develop its technology and gene therapy applications. Most clinical biotech stocks would kill to have more than $360 million in cash on their balance sheets.That cash will provide it plenty of working capital to develop its lucrative gene therapy portfolio.And lucrative it will be. VYGR is targeting Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease and Alzheimer's disease. These are some of the hardest diseases to crack and winners here will be massive achievements. It seems that Voyager may just get there.So far, results for the firm's tech have been pretty positive, which could explain all the major partnerships. Back in March, Voyager announced that its initial trial for VY-AADC demonstrated improvement in clinical measures for Parkinson's Disease. This success prompted VYGR to start phase II trials -- with results coming in mid-2020. Meanwhile, the firm is moving forward with initial trials with its other partners and developing a robust pipeline. With ample cash, VYGR has plenty of time to get these therapies through testing. Fast track designation from the FDA doesn't hurt either.All in all, VYGR represents a great gene therapy play thanks to its leading partners. Clearly, they see the good in the biotech stocksAt the time of writing, Aaron Levitt was long CRSP and VYGR stock More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Amid an Escalating Trade War * 5 REITs to Buy While They're Dirt Cheap * The Only 3 Marijuana Stocks You Need to Own Compare Brokers The post 3 Top Gene Therapy Stocks That Could Soar appeared first on InvestorPlace.

  • Moody's29 days ago

    J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns a provisional rating to One CMBS class of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB

    The transaction certificates are backed by a single fixed-rate loan collateralized by the borrowers' leasehold interests in the complex known as Osborn Triangle, which consists of three lab-office facilities, identified as 610 Main Street North (278,738 SF), 1 Portland Street (229,330 SF) and 700 Main Street (168,879 SF) along with a 650-stall parking garage. The property features 270 allocated parking spaces within Osborn Triangle's three-level, subterranean parking garage.

  • GlobeNewswire29 days ago

    CRISPR Therapeutics to Present at Upcoming Investor Conferences

    ZUG, Switzerland and CAMBRIDGE, Mass., May 29, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.

  • CNBClast month

    Highlights from CNBC's Healthy Returns conference

    CNBC's Healthy Returns Summit was held earlier this week in New York City, featuring keynote presentations and panel discussions on the future of the health-care industry. Topics ranged from controversial genetic-editing technique CRISPR to the way AI is changing the practice of drug discovery and medicine and reform of the U.S. health-care system. A Chinese scientist last year made history by using CRISPR technology to genetically modify two newborns, pushing the ethics of human germline gene editing to the forefront of public debate.

  • CNBClast month

    Highlights from CNBC's Healthy Returns conference

    CNBC's Healthy Returns Summit was held earlier this week in New York City, covering topics from controversial genetic-editing technique CRISPR to the way AI is changing the practice of drug discovery and medicine and reform of the U.S. health-care system. An audience of health-care leaders from the private and public sector shared their views. Here are some edited excerpts.

  • CNBClast month

    'We as a species need to come to terms' with CRISPR technology as China awaits birth of third genetically modified baby

    The scientific community is now struggling to grapple with the ethics of human germline editing as another woman pregnant with a gene-edited baby is soon due to give birth.

  • 5 Growthy Biotech Stocks to Buy Despite the Scrutiny
    InvestorPlacelast month

    5 Growthy Biotech Stocks to Buy Despite the Scrutiny

    One would think that the biotechnology sector is immune from trade tensions, but that is not the case. Biotech stocks are very much prone to selloffs during heightened global insecurity. In general, U.S-China trade tensions have derailed investor confidence. Growth sectors filled with unproven businesses, such as biotechs, have been hurt the most as uncertainty is anathema to investors during downturns.In particular, tariffs and trade barriers will raise prices for consumers and crimp economic output. Add the government scrutiny over drug prices and the desire for Medicare for all, and suddenly the prospects worsen for biotech companies.If the U.S. government does not make progress toward changing the drug development and approval process, drug prices will not fall as much as investors fear. Investors could pick the most established drug companies or those with strong prospects but do not yet have a product on the market.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks to Buy as the Trade War Reignites There are five biotech stocks investors could buy despite the scrutiny weighing on the sector. Biotech Stocks to Buy: Allergan (AGN)Source: Everjean via FlickrMarkets are scrutinizing the leadership of CEO Brent Saunders. A group of activist shareholders tried but failed to change the executive team. In many ways, Allergan (NYSE:AGN) management is disappointing investors in executing its turnaround and growth plan. The company reported first-quarter net revenue of $3.6 billion, down 2% from last year. Without exchange rate adjustments, core growth would have been up 4.4% Y/Y.Net income grew just 1.3% from last year to $3.79 a share. The company is committed to deploying capital to improve shareholder value. It bought back $800 million of its shares and has another $2 billion left in the plan. It cut net debt/EBITDA to 2.8 times and it increased its dividends by 3% to 74 cents a share.Headwinds: The breast implant regulatory changes hurt its Natrelle line. Though a drop in textured implant sales is a headwind, 90% of Allergan's business is with smooth implants. Five approvals over the next 18 months could offset that business plus weak Alloderm and Coolsculpting revenue. The company expects approval for Cariprazine, Abicipar, Bimatoprost SR, Ubrogepant and CoolTone next.Competition for Botox is still a worry but the company reported revenue of $868 million, up by a healthy 9%, from last year's levels. Even if competition heats up, Allergan benefits from brand recognition and an established customer base. As it improves the product, the company may potentially maintain its market share in 2019. Regeneron Pharmaceuticals (REGN)Source: Shutterstock Regeneron (NASDAQ:REGN) fell sharply lower from $400 to around $325 in recent weeks. Selling pressure on its shares accelerated after the company reported first-quarter results. Earnings fell 3.5% while revenue rose 13.3%. Before the report, REGN stock traded at a P/E in the high teens on expectations that the company would sustain the 26% annual growth reported over the last five years.Skepticism over Praluent and Eylea sales growth caused investors to re-evaluate the company's growth potential. Conversely, its atopic dermatitis drug generated $374 million in quarterly sales, helped by the sequential prescription growth of 18%. An expanded indication of the drug for adolescents and children will accelerate revenue. Markets are ignoring the potential of Dupixent becoming the biggest revenue contributor to the business in the next 2-3 years. The company also received approval for treating asthma, which will further drive sales.Recent Developments: Regeneron is spending plenty of developing drugs to treat cancer. And it has four to six new molecules that it expects will advance to the clinical stage this year. This is on top of the five molecules that advanced in 2018. * 10 Stocks That Could Squeeze Short Sellers, Including CGC Staff hiring and higher SG&A costs hurt profits in the quarter but should benefit the company's bottom line in the near future. Regeneron needs to spend more to support Dupixent for asthma and for the Libtayo launches. Looking ahead, lower promotional costs and higher staff efficiency should lead to higher profits. With REGN stock now at 16 times earnings, investors should take another look at this beaten down stock. XBiotech Inc. (XBIT)Source: Shutterstock Still trading in an uptrend that began last Sept. 2018, XBiotech (NASDAQ:XBIT) is worth another look. On Mar. 1, the company, which is effectively a potential competitor to Regeneron, reported breakthrough results. In its Phase 2 trial of Bermekimab for treating atopic dermatitis, XBiotech demonstrated high efficacy for subjects. The company posted that:After only seven weeks of treatment, 71% of patients that received a 400mg bermekimab weekly regimen had at least 75% reduction in their disease.Further, the company wrote:"Within 7 weeks, using [the] patient reported Numerical Rating Scale (NRS) for itch and pain, patients receiving the 400mg bermekimab treatment regimen had 71% reduction in itch and an 84% reduction in pain."XBiotech is clearly a contender in the eczema space. If it is an eventual competitor to Regeneron, why should investors consider this stock too? XBiotech is valued with a market capitalization of just $342 million. At that level, it could attract a suiter. More clinical results that reaffirm the drug's positive results could also drive the share price higher.In its third-quarter report, XBiotech had $20.85 million in cash and reported a GAAP EPS of a loss of 14 cents. The cash on hand should cover the clinical study costs in the near-term. As the company gets closer to applying for approval, the market may grow more bullish on its stock. Dermira Inc. (DERM)Source: DermiraDermira (NASDAQ:DERM) is also developing a drug in the atopic dermatitis space. Its market cap of $571 million is still above that of XBiotech. It would have been higher if the stock did not peak at $15 in early April, only to trade at $10.70 recently.The company launched Qbrexza, a product for treating excessive sweating, seven months ago. Investor interest grew when the company posted Phase 2b data for Lebri in March. Although Regeneron's Dupixent targets IL-4 and IL-13, Lebri targets IL-13 only. The company believes that IL-13 is the central pathogenic mediator associated with the AD pathophysiology. So if its drug treats the skin barrier dysfunction, the patient itch is reduced and skin infection complications averted.Dermira is finalizing its plans for the Phase 3 study and will meet with the FDA by mid-year. The study will potentially start by the end of 2019. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% First-Quarter Results: DERM stock fell after the company reported a GAAP EPS loss of $1.49. It generated revenue of $2.45 million. These figures have little meaning at this time because the stock's valuation depends on the clinical trial results for Lebri. For now, revenue growth will depend on Qbrexza prescriptions. Expect strong sales momentum: on the company's website, page views topped 50,000 unique weekly visitors. As the company accelerates brand awareness through advertising, the market share for Qbrexza will continue growing. CRISPR Therapeutics AG (CRSP)Source: Shutterstock Continuing on the theme of biotechnology stocks in the development phase, investors should consider buying CRISPR Therapeutics AG (NASDAQ:CRSP) as shares continue to rebound. The stock fell to as low as $22 last Dec. 2018 but climbed steadily throughout this year. CRSP stock traded recently at $39.10.The company's mandate is to create transformative gene-based medicines for serious diseases. The company has roots in developing a treatment for sickle cell but is expanding its market. In April, the FDA designated its therapy candidate CTX001 for fast track review. Together with its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), the drug, used for the treatment of transfusion-dependent beta thalassemia (TDT), could get to market sooner with the fast track.In February, the company announced that the first patient had been treated with CTX001 in a Phase 1/2 clinical study of patients with TDT. Enrollment for the study is ongoing.CRSPR's next-generation of I/O cell therapy will have two characteristics. First Allogeneic CAR-T will be off-the-shelf and will have more potent starting material. Second, it will have solid tumor efficacy. The benefits include targeting tumors with greater selectivity, avoiding exhaustion, and modulating suppressive TMEs (tumor microenvironments).First-Quarter Results: CRISPR reported a Q1 GAAP EPS loss of 93 cents. As a company still in the product development stage, investors need not be concerned. What is important is its cash balance of $437.5 million in cash as of March 31, 2019. With plenty of funds available to cover R&D costs, the company is unlikely to issue shares in the near-term.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy as the Trade War Reignites * 10 Stocks That Could Squeeze Short Sellers, Including CGC * 5 Tech Stocks Getting Crushed Compare Brokers The post 5 Growthy Biotech Stocks to Buy Despite the Scrutiny appeared first on InvestorPlace.

  • Why CRISPR Therapeutics Gained 13.4% in April
    Motley Fool2 months ago

    Why CRISPR Therapeutics Gained 13.4% in April

    CRISPR and partner Vertex bagged an important regulatory designation for CTX001 last month.

  • Genetics, CRISPR and Medical Ethics: CEO of Synthego, CRISPR Therapeutics and Stanford Medical's Hurlbut at Healthy Returns
    CNBC Videoslast month

    Genetics, CRISPR and Medical Ethics: CEO of Synthego, CRISPR Therapeutics and Stanford Medical's Hurlbut at Healthy Returns

    Genomic medicine's progress and future potential is hugely exciting, but it comes with enormous ethical implications. So how can we ensure its responsible use? CNBC's Meg Tirrell sits down with Synthego CEO Paul Dabrowski, CEO, Standford Medical School's Dr. William Hurlbut and CRISPR Therapeutics CEO Dr. Samarth Kulkarni.